Pharmacokinetics and Safety of Erenumab after a Single Subcutaneous Injection Dose in Healthy Chinese Subjects.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 7, p. 623, doi. 10.1007/s40261-022-01171-5
- By:
- Publication type:
- Article
Works matching IS 11732563 AND DT 2022 AND VI 42 AND IP 7
Results: 7
1
2
Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 7, p. 611, doi. 10.1007/s40261-022-01170-6
- By:
- Publication type:
- Article
3
Thromboembolic Events While Taking Direct Oral Anticoagulants: An Analysis of Post-market WHO Database Reports from 2012 to 2020.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 7, p. 593, doi. 10.1007/s40261-022-01165-3
- By:
- Publication type:
- Article
4
Guillain–Barré Syndrome Associated with COVID-19 Vaccines: A Perspective From Spontaneous Report Data.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 7, p. 581, doi. 10.1007/s40261-022-01164-4
- By:
- Publication type:
- Article
5
Pharmacological Anti-Remodelling Effects of Disease-Modifying Drugs in Heart Failure with Reduced Ejection Fraction.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 7, p. 567, doi. 10.1007/s40261-022-01166-2
- By:
- Publication type:
- Article
6
A Systematic Review of Neurocognitive Effects of Subanesthetic Doses of Intravenous Ketamine in Major Depressive Disorder, Post-Traumatic Stress Disorder, and Healthy Population.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 7, p. 549, doi. 10.1007/s40261-022-01169-z
- By:
- Publication type:
- Article
7
Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 7, p. 599, doi. 10.1007/s40261-022-01168-0
- By:
- Publication type:
- Article